| Document |
Document Title |
|
JP2015509496A |
It is provided for this specification, The unusually high level, the disease related as it is active, or state of TNF-alpha is treated or prevented. It is a new preparing method of the amino sulfone intermediate for composition of useful...
|
|
JP2015048332A |
To provide a compound for optical resolution capable of easily optically resolving the optical isomer mixture of amino acid at high sensitivity, and an optically resolving method using the compound.Provided is a compound for optical reso...
|
|
JP2013528577A5 |
|
|
JP2015505827A |
The present invention provides (*) *2* exo* morpholino iso ボルン *10* チオール and an efficient and economical synthesizing method of the chiral catalyst エナンチオマー (ed) and related. A new molecular entity and an asymm...
|
|
JP2015027979A |
To provide a novel optically active α-aminophosphonate derivative, and an efficient method of manufacturing the same.A compound of the general formula (1) is obtained by reacting thionophosphonoyl ketimine and phosphite diester by using...
|
|
JP2015504054A |
The present invention provides medical treatment of multiple sclerosis of medical treatment of multiple sclerosis which contains the phenyl carbamate compound as a part for a phenyl carbamate compound and validity and/or a pharmacy const...
|
|
JP5663154B2 |
Process for optical resolution of (3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl)nitrile (I) comprises separating enriched racemic or enantiomeric mixture of (3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl)nitrile into its two ena...
|
|
JP5662345B2 |
|
|
JP5656635B2 |
The present invention relates to the resolution by preferential crystallization of potassium salts of racemic omeprazole which is a solvate of ethanol and/or of ethylene glycol, which consists in converting the omeprazole to the potassiu...
|
|
JP2014516920A5 |
|
|
JP2015003861A |
To easily and efficiently produce (R)-2-amino-2-ethylhexanol that is useful as a pharmaceutical intermediate without carrying out a complicated operation.(R)-2-amino-2-ethylhexanol is produced by subjecting a N-benzylidene-2-amino ester ...
|
|
JP5646606B2 |
Disclosed is an antitumor agent which has higher antitumor activity than conventional antitumor agents, while having low toxicity. Specifically disclosed is an antitumor agent which is characterized by containing a phosphine transition m...
|
|
JP2014503480A5 |
|
|
JP2014527534A |
The present invention relates to spiro Ben Jill Amin * phosphine, a manufacturing method for the same, and its use. It is a compound which has the structure denoted by formula (I), is here, and is n=0*3;R.1R2R3R4R5R6R7R8R9A の value is ...
|
|
JP5605008B2 |
|
|
JP5605716B2 |
|
|
JP2014193895A |
To provide a method for purifying lactic acid on an industrial scale.(a) A lactic acid solution having, with respect to the weight of a concentrate lactic acid solution, a total acid content of at least 95 wt.% and a monomeric lactic aci...
|
|
JP5604520B2 |
The present invention relates to a compound of formula I, in all its isomeric forms and pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatm...
|
|
JP5603627B2 |
|
|
JP5603884B2 |
|
|
JP5603626B2 |
|
|
JP2014525895A |
This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy ...
|
|
JP2014520140A5 |
|
|
JP5598330B2 |
|
|
JP2014524885A |
The present invention targets [output of a preparing method of Ben Jill [(3aS, R / 4 / and 6S, 6aR) *6* hydroxy *2 and 2* ジメチル tetrahydro *3aH* cyclo ペンタ [d] [1, 3] ジオキソル *4* イル] carbamate (VI), (VI), and the ...
|
|
JP5596134B2 |
The present invention relates to a resolution process of (±)-methyl phenyl[4-[4-[[[4'-(trifluoromethyl)-2-biphenylyl]carbonyl]am
ino]phenyl]-1-piperidinyl]acetate to isolate the MTP (microsomal triglyceride transfer protein) inhibitor m...
|
|
JP5595404B2 |
|
|
JP2014172839A |
To provide a process for producing a tertiary alcohol derivative of high optical purity from a racemic tertiary alcohol derivative or a tertiary alcohol derivative of low optical purity.Provided is a method for producing an optically act...
|
|
JP2014172856A |
To produce a high-purity optically active tetrahydrofuran-2-carboxylic acid having optical activity efficiently with high productivity.There is provided a method for producing a high-purity (R)- or (S)-tetrahydrofuran-2-carboxylic acid, ...
|
|
JP2014169252A |
To provide a new method of producing optically active β-formyl-β-hydroxy-α-substituted aldehyde compounds.A method of producing an optically active β-formyl-β-hydroxy-α-substituted aldehyde compound (2) includes the step of making ...
|
|
JP2014523896A |
The present invention relates to the new nitryl compound shown in formulas I and II. (I) Formula I(The inside of a formula and X are *CH (s).)3Or it is *C≡N. (II) Formula II(The inside of a formula and X are *CH (s).)3Or as for R, Y is...
|
|
JP2014169294A |
To provide an optically active piperidine derivative which is excellent in antihistaminic activity and antiallergic activity, has little hygroscopicity and is excellent in physicochemical stability, and a manufacturing method thereof.Thi...
|
|
JP2014523416A |
Disclosed are 1,3-Dioxoindene derivatives of Formula 1, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprisin...
|
|
JP5585822B2 |
|
|
JP2014152156A |
To provide a method for obtaining an optically active material, when erythro ADPE or MA is used as a reagent for optical resolution, having a sign opposite to the previously obtained one without forming a diastereomeric salt again.To pro...
|
|
JP2014148531A |
To provide, among other things, novel compounds useful for treating bacterial infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effe...
|
|
JP2014520077A |
A crystalline mono hydrochloride salt of (4S,4aS,5aR,12aS)-4-dimethylamino- 3,10, 12, 12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]- 1, 11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carbox
ylic acid amide is disclosed having...
|
|
JP2014520140A |
The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D 1 and D 2 as well as the 5HT 2 receptors in the central nervous system, for use as a medicament and for the...
|
|
JP2014520126A |
The invention provides a new process for the preparation of solifenacin or a pharmaceutically acceptable acid addition salt thereof, comprising reacting (R)-quinuclidin-3-yl phenethylcarbamate with benzaldehyde in the presence of an acid...
|
|
JP5566103B2 |
|
|
JP5563830B2 |
The present invention relates to synthesis procedures and intermediates of a compound of formula: and the salts thereof.
|
|
JP2014133771A |
To provide processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity....
|
|
JP5553911B2 |
Provided is a process for preparing Voriconazole represented by Chemical Formula 1. More particularly, the process for preparing Voriconazole of Chemical Formula 1 includes: carrying out the Reformatsky-type coupling reaction between a k...
|
|
JP5557292B2 |
The problem to be solved is to provide a method for producing a compound having excellent activity as an ± 2 ´ ligand. The solution thereto is a method for producing a compound represented by the general formula (I) or a salt thereof b...
|
|
JP2014516920A |
The present invention relates to those use as *4* cyano *3 replaced (3R, 4R), 4* diphenyl butanoic acid compounds, those manufacturing methods, a weed killer, and a plant growth regulation agent. The compound of formula (I) in an optical...
|
|
JP5552422B2 |
(6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid calcium salt aqueous solution production involves methylating (6S)-5,6,7,8-tetrahydrofolic acid with a part of the corresponding (6R)-diastereoisomer in the range of 4-8 wt.% in water. Calciu...
|
|
JP5544298B2 |
The invention relates to compounds that are vitamin D receptor activators, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained durin...
|
|
JP2014122211A |
To provide an GPR40 activator containing a compound having a novel GPR40 agonist effect or a salt thereof or a solvate thereof and the like as an active ingredient, especially an insulin secretion promoter, a prevention and/or therapeuti...
|
|
JP5534460B2 |
|
|
JP5536869B2 |
A new process for the enantiomeric separation of racemic 3,6-dihydro-1,3,5-triazine derivatives for the treatment of disorders associated with insulin-resistance syndrome, by preferential crystallization.
|
